Where is NexImmune located?

NexImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland.

How many employees does NexImmune have?

As of Dec 31, 2022, NexImmune has 69 employees, reflecting a 57% year-over-year growth in headcount.

Is NexImmune a funded company?

NexImmune is a funded company, having raised a total of $36.3M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of NexImmune?

NexImmune's latest funding was a $***** Series A round on Feb 22, 2019, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $684M in funding in 2026 to date.

Where does NexImmune rank among its competitors?

NexImmune ranks 487th amongst 3192 active competitors, of which 1092 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of NexImmune?

NexImmune's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

NexImmune - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of immunotherapeutics for cancer. The company's lead products are AIM101, an APC-based injectable for solid tumor cancers, and AIM ACT, a cellular therapy to treat hematological malignancies. Also, developing therapies for cancer, type I diabetes, and viral diseases.

Website: neximmune.com
Email ID: *****@neximmune.com
Registered Address: Gaithersburg, Maryland

Key Metrics

Founded Year

2011

Location

Gaithersburg, United States

Stage

Public

Total Funding

$36.3M in 10 rounds

Latest Funding Round

Series A, Feb 22, 2019, $*****

Investors

New Enterprise Associates & 14 more

Ranked

487^th among 3192 active competitors

Employee Count

69 as on Dec 31, 2022

Similar Companies

Jazz Pharmaceuticals & 2965 more

Exit Details

Public

View NexImmune's full profile

NexImmune is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neximmune, Inc. CIN: 452518457 , United States, Active	Jun 06, 2011	-	69 (As on Dec 31, 2022)	-

NexImmune got listed on Feb 12, 2021.

Click here to take a look at NexImmune's IPO in detail

NexImmune has raised a total funding of $36.3M over 10 rounds. NexImmune has 15 institutional investors.

Here is the list of recent funding rounds of NexImmune:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2019	1404144	Series A	3733513	2989703	6673980	2099846
Jan 02, 2018	3717899	Series A	6527377	4110904	7383539	Piedmont Capital Partners & 1 more
Feb 13, 2015	5907256	Series A	4237343	3214244	3504359	7393883

Access funding benchmarks and valuations. Sign up today!

View details of NexImmune's funding rounds and investors

NexImmune's employee count trend

NexImmune has 69 employees as of Dec 22. The total employee count is 57.0% more than what it was in Dec 21. Here is NexImmune's employee count trend over the years:

Uncover NexImmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NexImmune include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of NexImmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, BB Biotech & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
487th	NexImmune 2011, Gaithersburg (United States), Public	Developer of immunotherapeutics for cancer	$36.3M	Amgen Business Development, ArrowMark Partners ... & 13 others	53/100